NDC product
doxorubicin hydrochloride, Liposomal
NDC 0338-9581 · Baxter Healthcare Corporation
Key facts
| Product NDC | 0338-9581 |
|---|---|
| Proprietary name | doxorubicin hydrochloride, Liposomal |
| Nonproprietary name | doxorubicin hydrochloride |
| Substances | DOXORUBICIN HYDROCHLORIDE |
| Dosage form | INJECTION, SUSPENSION, LIPOSOMAL |
| Route | INTRAVENOUS |
| Labeler | Baxter Healthcare Corporation |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | UNAPPROVED DRUG FOR USE IN DRUG SHORTAGE |
| Pharmacologic classes | Anthracycline Topoisomerase Inhibitor [EPC], Anthracyclines [CS], Topoisomerase Inhibitors [MoA] |
| Marketing start | Dec 19, 2023 |
| Listing certified through | Dec 31, 2026 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: